Clean Vision Corporation (OTC: CLNV) has experienced several interesting developments recently, but it hasn’t noticeably influenced the market with any substantial gains. Nonetheless, we believe it’s worth providing an update on the company given it’s been a few months since our last mention. In today’s discussion, we’ll explore a variety of updates and their significance, with aim of providing insight on what to expect for 2024.

Background:

Clean Vision is led by Dan Bates, and their goal is to tackle the global plastic waste crisis head-on. Their wholly owned subsidiary, Clean Seas, has developed the Plastic Conversion Network (PCN), a groundbreaking technology aimed at diverting millions of tons of waste plastic from landfills, incineration, and oceans. The PCN converts this plastic feedstock into clean fuels and green hydrogen, significantly reducing reliance on fossil fuels and lowering the carbon footprint.

For a brief 2 minute overview on the company, feel free to reference the video CLNV’s subsidiary put together on YouTube. Here’s the link.

Clean Seas utilizes proven pyrolysis technology to produce environmentally friendly products, which are sold to multinational petrochemical companies, driving the circular plastic economy. Operational PCN facilities are already in place in Morocco and India, with additional conversion facilities in development across West Virginia, Arizona, and Southeast Asia. Long-term feedstock supply agreements exceeding one million tons of waste plastic annually have been secured at no cost.

Their recently trademarked brand, AquaH®, is produced in their PCN. According to the release, it offers a differentiated green hydrogen product from carbon-neutral sources. Currently, hydrogen is predominantly produced through methods that involve fossil fuels, which of course contributes to global carbon emissions. Furthermore according to Deloitte’s 2023 global green hydrogen outlook, this could be a $1.4T annual market by 2050.

$65 Million Plastic Conversion Facility:

CLNV is making big moves in West Virginia and according to the release on October 24th, 2023, they’ve brought in some serious players—CDI Engineering Solutions and ERM—to help out with their Clean-Seas West Virginia project.

CDI has over 70 years of experience integrating engineering, design, project support, procurement and construction management services to the energy, chemicals and electrical infrastructure markets.

ERM is the world’s largest advisory firm focused solely on sustainability, offering environmental, health, safety, risk and social expertise for more than 50 years with more than 8,500 dedicated professionals operating across 40 countries.

The plan is to kick things off in 2024, turning 100 tons of plastic every day into recycled plastics and clean fuels. It’s a hefty project with a $65 million investment, creating over 200 jobs initially. And they’re not stopping there—they want to scale up to 500 tons of plastic per day over time.

West Virginia Governor Jim Justice is also on board, throwing over $12 million in state incentives to support the project.

Governor Jim Justice made a reference to Clean Seas in his state of the union address. If you want to catch the mention, go to 34:15 in the video. The three minutes leading up to it are also worth reviewing.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Launches Global Operations:

CLNV made another significant advancement, planning to launch waste plastic conversion facilities in the European Union, Eastern Europe, and Southeast Asia. This will be accomplished through their new subsidiary, Clean-Seas Partners UK Limited (CS-UK), who of course shares the same vision of creating sustainable solutions to the global plastic pollution crisis.

Under the leadership of Managing Director Shaun Wootton, CS-UK will play a crucial role in strategic project development and investment facilitation, leveraging established relationships in the Middle East, Southeast Asia, and Europe.

To fortify effective governance and strategic direction, CS-UK is assembling a distinguished board with internationally recognized figures in banking, sustainability, and energy. This approach aims to have a diverse and experienced board guiding CS-UK in realizing its vision of promoting sustainability and environmental stewardship across diverse regions.

$340 Million Bond Offering:

CLNV even announced they partnered with a global advisory firm, Grant Thornton, to issue up to $340 million in Green Bonds. This is the world’s sixth-largest network of independent accounting and consulting firms, employing 62,000 people in more than 130 countries and had revenues of $6.6 billion in 2021. These bonds will fund the expansion of Clean Vision’s Plastic Conversion Network (PCN) under the “Clean-Seas” initiative worldwide, aimed at combatting plastic pollution on a global scale.

With the Green Bond’s net proceeds, CLNV plans to deploy at least six plastic waste conversion lines globally, with strategic locations in West Virginia, Arizona, Southeast Asia, and expansion in Morocco. The Green Bond is also expected to attract environmentally conscious investors, setting a new standard for corporate responsibility.

$15M Government Loan:

Lastly, under the capable management of Huntington Bank, CLNV has recently secured a $15 million government loan. What sets this apart is that the loan is FORGIVABLE.

A forgivable loan is a type of loan where the borrower is not required to repay the borrowed amount under certain conditions. Typically, these conditions are related to the borrower meeting specific criteria, such as using the funds for approved purposes, maintaining certain employment levels, or achieving predetermined goals. If the borrower fulfills these conditions, the loan is forgiven, and they are not obligated to repay the borrowed amount. Forgivable loans are often used as an incentive or support for specific activities, such as job creation, small business development, or other initiatives that contribute to economic growth or community welfare.

Not to mention it won’t result in any dilution for shareholders. This is an unexpected and uncommon accomplishment for an OTC company. Securing a government loan of this size without any dilution is truly impressive.

Conclusion:

CLNV has made impressive strides tackling the global plastic waste crisis, especially given their valuation of merely $22.65 million. The team has swiftly achieved key objectives, including a $65 million plastic conversion facility in West Virginia, global expansion through Clean-Seas Partners UK Limited, a $340 million Green Bond Offering, and a remarkable $15 million forgivable government loan. The vast $1.4 trillion market they’re tapping into offers an interesting opportunity with current indicators looking positive. Nevertheless, it’s crucial to acknowledge that there is still significant work ahead, and the team needs to maintain consistent execution to turn this potential into a reality.

We will update you on CLNV when more details emerge, subscribe to Microcapdaily to follow along!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by pasja1000 from Pixabay

Integrated Cannabis Solutions (OTC: IGPK) has undergone a remarkable uptrend, surging an impressive 633% since December 11th, 2023, with 166% of that surge taking place across yesterday’s trading session and today, January 11th, 2023. Both days have been marked by unprecedented volume – Yahoo Finance reported an almost 30x increase, with 115,867,027 shares traded by close yesterday. We’re already seeing 90,092,317 shares traded this morning and it’s just barely noon. Today we’ll explore the catalysts behind the surge, offer a comprehensive overview of the company, and evaluate IGPK’s potential for sustained growth throughout 2024.

Background:

Let’s get straight to it. IGPK is the result of a recent reverse merger with Integrated Cannabis Solutions and JFH Digital E-Commerce Corp. The first thing you’ll notice is finding the website isn’t a walk in the park, we’re fairly certain there isn’t one yet, at least one that will help in any way related to more investment information. Your best bet for more any information is to check out IGPK’s OTC Market page for details, but even the company description on there is not accurate. We’ve mainly found the following information through filings, IGPK’s Twitter, and other online users.

Keep in mind this breakdown might not be flawless given we’re piecing it together mostly from what folks on X are saying. But we’ll try our absolute best to lay it all out for you.

IGPK appears to have been a shell for little while until JFH stepped in. A user on X, @stockplayer30, broke it down fairly simply, stating that the shell’s slate was wiped clean, cancelling all notes payable and any debt. Whether it’s a promissory note, convertible note, or convertible debenture, the main point is they ditched all debt. JFH has an opportunity to start fresh, and it certainly makes this deal a lot more interesting.

Just a heads up, it’s a Chinese merger. If the idea of a Chinese leadership team makes you a bit wary, you might want to pause here. However if you were in the trading game during the summer of ’23, you probably remember those crazy spikes in some Chinese Nasdaq deals. And get this – no big press releases or SEC filings to explain those sudden jumps either.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Company Description:

Onto what the company actually does. According to @SuperRobotOTC on X, this is a digital e-commerce company based in China, here’s a link to their e-commerce website. This user also put together a great overview of the company on YouTube, if you’d like to watch something informative in video format, click here.

Another user, @igal_n, found a blurb on the company that states, “Junfenghuang (JFH) is a digital asset. It is a token issued by Uplus Future Company with the help of blockchain technology. It has no direct relationship with the original equity”.

The Potential:

What makes this story extremely interesting is the sheer magnitude of how large JFH is, the intrinsic value does not appear to be valued accurately in the market, given it’s only freshly merged into IGPK’s tiny shell company on the OTC.

Their Gross Merchandise Value (GMV) is heading north of 50 billion yuan, and post-merger profits from service outlets are looking at a hefty 10 billion yuan – yes, billion with a B.

Steering the ship is a leadership team featuring President Wang Dejun, Treasurer Xie Weiji, and Director Yang Lanfang. With a whopping 750 subsidiaries, 250,000 merchants, and 30 million registered users. We’ve also heard from other sources that the registered users could be nearly double that, coming in at 50 million registered users.

These numbers are substantial for a company with a $7 million market cap. Looking ahead, it won’t be shocking if IGPK sets its sights on moving up to a bigger exchange like NASDAQ. It’s no secret they’re already in the big leagues – or it at least appears so. If that were the case, they’d of course have enhanced credibility, more visibility, and increased access to capital with institutional funding.

The App:

Now, you might be wondering, “Sounds cool, but it’s a Chinese merger with a whole setup on the other side of the planet. Can we trust this info?” @SuperRobotOTC has also gone the extra mile by downloading the app, and gave us the lowdown in video format. On top of the SEC filings, this is an added layer of trust & credibility we can attribute to this new venture. Here’s the link to the video.

Conclusion:

Fortunately it appears IGPK is still for the most part flying under the radar. There’s not even a proper website or accurate update on IGPK’s OTC Market overview to tell us what the company even entails. But here’s the silver lining – that might mean you’re still early. The intrinsic value of IGPK appears strongly disproportionate to its current value in the market.

Our advice? Keep a close eye on IGPK’s journey as it takes on this exciting phase of growth and exploration. It’s likely this story will catch wind quickly and it could be a great time to take advantage. As @SuperRobotOTC eluded to in his video, this could be the OTC’s largest merger, with a potential $70B valuation.

We will update you on IGPK when more details emerge, subscribe to Microcapdaily to follow along!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by geralt from Pixabay

Sonoma Pharmaceuticals (NASDAQ: SNOA) has been navigating through unpredictable market fluctuations lately, experiencing a noteworthy surge of approximately 32% today on January 10th, 2024. Although this might seem modest when juxtaposed with our other coverage & articles, our interest in SNOA lies in its promising trajectory and the speculations circulating among online users.

In the realm of biopharmaceuticals, SNOA finds itself amidst a pool of undervalued companies grappling with the challenging landscape of venture market conditions given the current cost of capital for companies that are pre-profitability. Since its funding round on October 18, the stock has witnessed a staggering 80% decline, settling at what appears to be rock bottom levels.

The critical question looming is whether there is untapped potential from the current levels. According to insights gathered from online discussions, the consensus is optimistic. But before we delve into the specifics, let’s establish some foundational background information.

Background:

SNOA is a key player in the global healthcare scene, specializing in the development and production of stabilized hypochlorous acid (HOCl) products. These versatile products find applications in various healthcare areas, such as wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and as non-toxic disinfectants.

What sets Sonoma’s products apart is their ability to tackle infections, alleviate itch and pain, reduce scarring, and counter harmful inflammatory responses in a safe and effective manner. Extensive in vitro and clinical studies of HOCl have underscored its impressive properties, including being antipruritic, antimicrobial, antiviral, and anti-inflammatory.

The magic of Sonoma’s stabilized HOCl lies in its immediate relief of itch and pain, pathogen-killing prowess, biofilm breakdown ability, all without causing any stinging or irritation to the skin. Additionally, it aids the natural healing process by oxygenating the cells in the treated area.

Sonoma’s products have made their mark in 55 countries worldwide, either through direct sales or partnerships, and the company actively seeks new distribution collaborators. Headquartered in Boulder, Colorado, Sonoma operates manufacturing facilities in Latin America, while its European marketing and sales hub is located in Roermond, Netherlands.

Breakdown On The Technology:

Let’s talk about their Microcyn® Technology, a stabilized triple-action topical technology.

Multifaceted benefits…

• Powerful Anti-Microbial: Effectively diminishes microbial load, demonstrating prowess in biofilm destruction.
• Anti-Inflammatory Agent: Exhibits anti-inflammatory properties, providing relief from itch and pain.
• Anti-Pruritic Activity: Proven effectiveness in alleviating itching, enhancing overall comfort.
• Tissue Healing: Stimulates increased blood and oxygen flow to wounds, fostering a conducive environment for tissue recovery.

Safety profile…

• No Drug Interactions or Contraindications: Demonstrates compatibility without risking complications arising from drug interactions.
• Proven Safety: With millions of patients treated globally, there hasn’t been a single report of a serious adverse effect.
• Rigorous Clinical Trials: Backed by 30+ human clinical trials involving over 1,500 patients, providing a robust foundation of evidence.

Product Efficacy…

• No Mutations or Resistance: In contrast to overused antibiotics that may lead to dangerous epidemics like MRSA, this solution offers a sustainable alternative.
  Not just groundbreaking in its effectiveness, this product also stands as a cost-effective solution:
• Preventative Measures: Reduces the need for frequent hospital or physician visits, proving valuable in a preventative capacity.
• Savings for Medicare/Hospitals: Accelerates healing, subsequently reducing hospital stays and presenting a practical avenue for cost savings.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Latest Press Release:

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) and SNOA entered into an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The collaboration involves combining Sonoma’s existing eye product, Ocudox®, which has received approval for sale in the European Union, with the Avenova brand. These products will be marketed through Sonoma’s established European distribution network.

Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products, recognized as the leading hypochlorous acid-based eye care items in the United States. Sonoma will pay NovaBay a royalty fee based on the sales of Ocudox by Avenova. Importantly, Sonoma will continue marketing its Ocudox product independently in the European Union.

The partnership is seen as an opportunity for both companies to leverage their strengths. Sonoma, with its strong presence in the European Union, aims to expand its eye care offerings by adding Avenova-branded products. NovaBay anticipates the European market to be comparable in size to the U.S., providing an opportunity to double its sales of Avenova. NovaBay will maintain exclusivity in selling Avenova-branded products in the U.S.

So What:

Typically investors are left to their own accord to decipher the importance of a release, here’s a further breakdown as to why this partnership is beneficial for SNOA:

• European Expansion: Sonoma can now broaden its eye care offerings in the EU with the addition of Avenova-branded products, diversifying its portfolio.
• Strategic Combo: Merging Sonoma’s Ocudox® with Avenova branding combines Sonoma’s global distribution expertise with Avenova’s established name, creating a unique product for the European market.
• Financial Boost: Producing Ocudox by Avenova generates a royalty fee for Sonoma, enhancing its financial stability.
• Smart Positioning: The collaboration strategically leverages Sonoma’s EU presence and Avenova’s U.S. dry eye market recognition, strengthening Sonoma’s competitive position.
• Blepharitis Solution: Sonoma’s CE-marked Ocudox by Avenova addresses blepharitis, offering a valuable solution for a prevalent eye health issue in Europe.
• Market Growth: Recognizing the EU’s market size comparable to the U.S. signals significant growth potential for Sonoma, aligning with its goal to expand its eye care offerings.

Market Cap vs. Cash Position:

As it stands, SNOA’s current market capitalization hovers around $2.8 million, closely mirroring its $2.9 million cash position on the balance sheet. This doesn’t mark the most substantial market cap to cash comparison on record, it’s not entirely unprecedented to witness companies trading with cash holdings two or even three times their market cap. But nonetheless, this observation is still important. In the scenario of a complete business sell-off, the cash reserves alone would surpass the company’s entire valuation.

This calculation wouldn’t even account for their assets or potential future cash flows of products. The company has 21 FDA clearances for its medical devices, got CE marks for over 39 products, and has the green light from regulators worldwide. All of this is packed into a market cap of just $2.8 million…

Low Float:

Adding to the intrigue surrounding SNOA is its remarkably low float, standing at just 13.43 million shares. As many of you are likely aware, the float represents the shares available for trading in the open market, and this can potentially bode well for a public company. Here’s why:

• Price Volatility: With a low float, there is the potential for increased price volatility. Limited supply and heightened demand can lead to more significant price swings, which can attract short-term traders and investors seeking quick returns.
• Responsive to News: Public companies with a low float tend to be more responsive to positive news or strong financial results. The limited number of shares available can result in a quicker and more pronounced market reaction, potentially driving the stock price higher.
• Strategic Control: A low float provides management and major stakeholders with more strategic control over the company’s direction. It becomes easier to influence stock movements, attract investor attention, and implement changes in response to market dynamics.
• Potential for Rapid Appreciation: In certain situations, a low float can contribute to rapid stock appreciation. Increased demand, whether due to positive developments or investor sentiment, can result in a quicker uptrend in share prices.
• Takeover Attractiveness: Companies with a low float may be perceived as more attractive acquisition targets. A potential acquirer may find it easier to accumulate a significant stake in the company, leading to increased buyout interest and potentially higher acquisition premiums.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Short Squeeze Potential:

We couldn’t help but take notice of the substantial off-exchange short interest, currently standing at around 53%.

Off-exchange short interest refers to the level of short positions held by traders or institutions that are executed outside of the traditional exchanges. These trades often take place in dark pools, which are private forums for trading securities away from public scrutiny.

The reported dark pool short interest may not perfectly capture the entire market sentiment, but it’s an important factor to keep on your radar. In the world of investments, a high dark pool short interest is definitely worth noting, and SNOA’s is fairly high.

Now, consider the scenario of a potential short squeeze. Could SNOA opt for additional dilution to raise funds at a higher valuation if one occurs?

Maybe, but according to insights from @MoonMarket_, it seems unlikely. In February 2023, SNOA had an ATM open for $420,838, but the remaining capacity is now $0, implying that the company is less likely to exert downward pressure on the share price.

On top of this, it’s worth highlighting that SNOA boasts enough cash runway to last another year, suggesting that they might not be in a hurry to dilute investors.

Conclusion:

In the grand scheme, SNOA’s current valuation presents an intriguing mix of indicators, with some financial influencers on X also signaling at potential near-term appreciation. However it’s crucial to exercise caution, considering the online landscape is peppered with traders who may not always be on the mark—just as even top research analysts can make mistakes. Nevertheless, the multitude of factors at play makes SNOA a particularly interesting stock. As is customary with such companies, developments unfold swiftly, so be sure to maintain a vigilant watch.

We will update you on SNOA when more details emerge, subscribe to Microcapdaily to follow along!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by StockSnap from Pixabay.com